New drug combo tested for Tough-to-Treat blood cancers
NCT ID NCT07071155
Summary
This early-stage study is testing whether adding an oral drug called momelotinib to a standard injected therapy (azacitidine) is safe and effective for people with certain rare, overlapping blood cancers. The goal is to better control the disease, reduce symptoms like an enlarged spleen, and improve quality of life. The study will enroll about 18 adults who have not responded well to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.